Bevacizumab continued beyond first progression beneficial in patients with metastatic colorectal cancer previously treated with bevacizumab and chemotherapy

A new study has confirmed that continuing bevacizumab treatment beyond first progression, while modifying chemotherapy, can be beneficial for patients with metastatic colorectal cancer. In the first randomized study to prospectively investigate the impact of bevacizumab continuation in this setting, the study researchers noted a significant improvement in both overall and progression-free survival. Read more here.